Roche CERA submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche's long-acting anemia agent CERA has an estimated mid-February 2007 user fee date following the firm's recent submission of a BLA, announced April 20. The firm is seeking an indication for anemia associated with chronic kidney disease. Roche highlighted the continuous erythropoietin receptor activator as having a distinct molecular interaction from that of other erythropoietin agents. The BLA is supported by six Phase III trials of patients treated every four weeks. Roche is continuing to point to CERA's dosing advantages. The firm also plans to submit a chemotherapy-induced anemia BLA in 2009 (1Pharmaceutical Approvals Monthly February 2006, p. 15)...
You may also be interested in...
Roche Delays CERA Oncology Filing Until 2009
Roche is pushing back the timeline for filing its anti-anemia agent CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the firm said Feb. 1
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.